| Description |
| Product Type |
Product Size |
| Injection
|
1'S |
| Product Company |
| GP Pharm |
Leuprorelin Acetate 22.5mg
|
| Product Type |
Product Size |
| injection |
1'S |
| Product Company |
| Pharmedic |
Dacarbazine 200mg |
| Product Type |
Product Size |
| Tablet |
60'S |
| Product Company |
| Pharma Solution |
Sorafenib 500mg |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Pharmedic |
|
| Product Type |
Product Size |
| Capsules |
100'S |
| Product Company |
| Pharmedic |
Hydroxyurea 500mg |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Bevacizumab 100mg/4ml |
| Content | Leuprolide is a peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty."
| Dacarbazine, also known as imidazole carboxamide, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. For Hodgkin's it is often used together with vinblastine, bleomycin, and doxorubicin. | Sorafenib is used to treat late-stage kidney cancer (advanced renal cell carcinoma), liver cancer (hepatocellular carcinoma) that cannot be treated by surgery, and differentiated thyroid cancer that has come back or spread to other parts of your body.
| Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. | Hydroxyurea is in a class of medications called antimetabolites. Hydroxyurea treats cancer by slowing or stopping the growth of cancer cells in your body. Hydroxyurea treats sickle cell anemia by helping to prevent formation of sickle-shaped red blood cells. | "
Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. |
Reviews
There are no reviews yet.